Like most websites The Cannabis Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Profession COVID-19, Business

Pandemic Pressure Points

The good...

Cannabis dispensaries in many territories are being classified as “essential businesses,” alongside pharmacies and food shops – a move welcomed by industry associations and patient groups. Meanwhile, cannabis companies are rallying to join the fight against the virus. A number of cannabis extraction labs are leveraging existing ethanol supply chains to produce much-needed hand sanitizer at high volume, some of which is being donated to police, firefighters, and healthcare staff. Regulated cannabis labs in Canada have even been approached by the government about carrying out COVID-19 testing.

Keep your stories coming about what you are doing to support your communities in these troubling times - email [email protected]

The bad...

The economic implications of the pandemic will be looming large in the minds of cannabis companies and investors after a tough year for the industry. US companies’ problems may be compounded by the fact that they are excluded from government financial aid due to the illegal status of the drug at a federal level. Many conferences are being postponed or canceled, including CannaTech Tel Aviv and Cannabis Science Conference East.

And the ugly...

The FDA has issued warning letters to several CBD companies for making false health claims about COVID-19. The agency encourages reporting false claims via an online form here. The International Association for Cannabinoid Medicines board said in a statement, “Several laboratory studies suggest that cannabinoids may have antiviral and antibacterial effects [...] However, there is no evidence that individual cannabinoids – such as CBD, CBG, or THC – or cannabis preparations protect against infection with the SARS-CoV-2 virus or could be used to treat COVID-19.”

Receive content, products, events as well as relevant industry updates from The Cannabis Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Charlotte Barker

Associate Content Director

After studying biology at Imperial College London, I got my start in biomedical publishing as a commissioning editor for healthcare journals, and I’ve spent my career covering everything from early-stage research to clinical medicine. Attracted by the creativity, talent and passion of the team, I joined Texere Publishing in 2014, where I’m now Associate Content Director and Editor of The Cannabis Scientist.

Register to The Cannabis Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Cannabis Scientist magazine